发布求助
文献互助 智能选刊 最新文献

Dermatology Reports最新文献

筛选
英文 中文
Definitive histology control after Mohs micrographic surgery: pleonastic or not?
IF 2.3
Dermatology Reports Pub Date : 2023-08-29 eCollection Date: 2024-09-02 DOI: 10.4081/dr.2024.9827
Ernesto De Piano, Vittoria Cioppa, Valentina Ongaro, Filomena Russo, Pietro Rubegni, Clelia Miracco
{"title":"Definitive histology control after Mohs micrographic surgery: pleonastic or not?","authors":"Ernesto De Piano, Vittoria Cioppa, Valentina Ongaro, Filomena Russo, Pietro Rubegni, Clelia Miracco","doi":"10.4081/dr.2024.9827","DOIUrl":"10.4081/dr.2024.9827","url":null,"abstract":"","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"16 3","pages":"9827"},"PeriodicalIF":2.3,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blastic plasmacytoid dendritic cell neoplasm: a short review and update. 大疱性浆细胞树突状细胞瘤：简短回顾与最新进展。
IF 2.3
Dermatology Reports Pub Date : 2023-08-11 eCollection Date: 2024-05-07 DOI: 10.4081/dr.2023.9781
Cesare Massone, Giulia Rivoli, Simona Sola, Emanuele Angelucci
{"title":"Blastic plasmacytoid dendritic cell neoplasm: a short review and update.","authors":"Cesare Massone, Giulia Rivoli, Simona Sola, Emanuele Angelucci","doi":"10.4081/dr.2023.9781","DOIUrl":"https://doi.org/10.4081/dr.2023.9781","url":null,"abstract":"<p><p>Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm (less than 1% of primary cutaneous lymphomas and acute leukemia) with a highly aggressive clinical course and frequent skin, bone marrow and central nervous system involvement. Even though there is often an early response to chemotherapy, leukemic dissemination relapses are very common and result in poor outcomes, with a median overall survival of 8 to 14 months in the first-line setting using standard combination chemotherapy regimens. Almost 90% of patients experience skin involvement as their initial site of infection, where BPDCN may stay restricted for weeks or even months until a swift secondary phase involving multiple organs takes place. Consequently, it is crucial to suspect and identify early skin lesions, as well as to conduct and report a skin biopsy as soon as possible. In order to diagnose and treat BPDCN, a multidisciplinary strategy involving collaboration between pathologists, hematologists, and dermatologists is unquestionably essential.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"16 Suppl 2","pages":"9781"},"PeriodicalIF":2.3,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blastic plasmacytoid dendritic cell neoplasm: a short review and update 母浆细胞样树突状细胞肿瘤:综述与最新进展
Dermatology Reports Pub Date : 2023-08-11 DOI: 10.4081/dr.2021.9781
Cesare Massone, Giulia Rivoli, Simona Sola, Emanuele Angelucci
{"title":"Blastic plasmacytoid dendritic cell neoplasm: a short review and update","authors":"Cesare Massone, Giulia Rivoli, Simona Sola, Emanuele Angelucci","doi":"10.4081/dr.2021.9781","DOIUrl":"https://doi.org/10.4081/dr.2021.9781","url":null,"abstract":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm (less than 1% of primary cutaneous lymphomas and acute leukemia) with a highly aggressive clinical course and frequent skin, bone marrow and central nervous system (CNS) involvement. Despite a frequent initial response to chemotherapy, relapses with eventual leukemic dissemination are extremely common, leading to poor outcomes and a median overall survival (OS) ranging from 8 to 14 months in first line setting, with standard combination chemotherapy regimens. The skin is the first affected site (in almost 90% of patients) where BPDCN may remain confined for weeks or even months (sanctuary?) until a rapid second step with multiorgan involvement occurs. Therefore, it is of uppermost importance to suspect and recognize early skin lesions and to perform and report a skin biopsy as soon as possible. A multidisciplinary approach with coordination among dermatologists, pathologists and hematologists is definitively crucial in diagnosis and management of BPDCN.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135397364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Langerhans cell histiocytosis presenting as a blueberry muffin rash 朗格汉斯细胞组织细胞增多症表现为蓝莓松饼疹
Dermatology Reports Pub Date : 2023-08-09 DOI: 10.4081/dr.2023.9791
Shahad F. Alanazi, Yara Jazzar, Tala Beidas, Haya Soufan, Khaled A. Mohajer, Abdulmalik Alhammad
{"title":"Langerhans cell histiocytosis presenting as a blueberry muffin rash","authors":"Shahad F. Alanazi, Yara Jazzar, Tala Beidas, Haya Soufan, Khaled A. Mohajer, Abdulmalik Alhammad","doi":"10.4081/dr.2023.9791","DOIUrl":"https://doi.org/10.4081/dr.2023.9791","url":null,"abstract":"Langerhans cells, often referred to as the “macrophages of the skin”, are dendritic cells that normally reside in the epidermis and papillary dermis. Just like macrophages, they function as antigen-presenting cells that activate naive T cells. Certain mutations such as those involving the BRAF gene can cause unopposed production of Langerhans Cells, which is known as Langerhans Cell Histiocytosis (LCH). LCH triggers an inflammatory immune response that causes systemic manifestations such as fever and fatigue, as well as other manifestations depending on the affected organs. The pathogenesis behind LCH remains poorly understood. It is still unknown whether it is a neoplastic process or a reactive cancer-mimicking illness. Diagnosis of LCH is confirmed by biopsy, and treatment is largely dependent on the extent and severity of the disease. Common treatments include corticosteroids, excision, radiation, and chemotherapy. We present a case of a 1-year-old Saudi male with LCH.","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135696865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome. 联合使用环孢素 A 和甲基强的松龙治疗小儿史蒂文斯-约翰逊综合征/毒性表皮坏死重叠综合征。
IF 2.3
Dermatology Reports Pub Date : 2023-06-19 eCollection Date: 2023-06-07 DOI: 10.4081/dr.2023.9656
Shinta Trilaksmi Dewi, Laily Noor Qomariah, Widya Khairunisa Sarkowi, Monika Puspitasari, Miya Khalidah, Marcella Anggatama, Dwinanda Almira Rizkiani, Kristiana Etnawati, Sri Awalia Febriana
{"title":"Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome.","authors":"Shinta Trilaksmi Dewi, Laily Noor Qomariah, Widya Khairunisa Sarkowi, Monika Puspitasari, Miya Khalidah, Marcella Anggatama, Dwinanda Almira Rizkiani, Kristiana Etnawati, Sri Awalia Febriana","doi":"10.4081/dr.2023.9656","DOIUrl":"10.4081/dr.2023.9656","url":null,"abstract":"<p><p>The treatment of epidermal necrolysis in pediatric patients remains a major challenge. Cyclosporine A has emerged as a promising therapy for epidermal necrolysis in adults; however, its efficacy in children is unclear. We present the case of a boy with Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome who was initially resistant to methylprednisolone monotherapy but improved after receiving the combination of cyclosporine A and methylprednisolone. Published reports on the use of cyclosporine A for pediatric epidermal necrolysis are also briefly reviewed.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9656"},"PeriodicalIF":2.3,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/82/dr-15-2-9656.PMC10327664.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9811484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights. 关注季节性自身免疫性大疱性疾病的环境因素：新见解。
IF 1.1
Dermatology Reports Pub Date : 2023-06-14 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9641
Roberto D'Astolto, Lavinia Quintarelli, Alberto Corrà, Marzia Caproni, Luca Fania, Giovanni Di Zenzo, Biagio Didona, Giulia Gasparini, Emanuele Cozzani, Claudio Feliciani
{"title":"Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights.","authors":"Roberto D'Astolto,&nbsp;Lavinia Quintarelli,&nbsp;Alberto Corrà,&nbsp;Marzia Caproni,&nbsp;Luca Fania,&nbsp;Giovanni Di Zenzo,&nbsp;Biagio Didona,&nbsp;Giulia Gasparini,&nbsp;Emanuele Cozzani,&nbsp;Claudio Feliciani","doi":"10.4081/dr.2023.9641","DOIUrl":"https://doi.org/10.4081/dr.2023.9641","url":null,"abstract":"<p><p>Autoimmune bullous diseases are a heterogeneous group of rare conditions clinically characterized by the presence of blisters and/or erosions on the skin and the mucous membranes. Practically, they can be divided into two large groups: the pemphigoid group and the pemphigus group, depending on the depth of the autoimmune process on the skin. A family history of autoimmune diseases can often be found, demonstrating that genetic predisposition is crucial for their development. Moreover, numerous environmental risk factors, such as solar radiation, drugs, and infections, are known. This study aimed to evaluate how seasonality can affect the trend of bullous pemphigoid and pemphigus vulgaris, especially considering the number of hospitalizations recorded over the course of individual months. The total number of hospitalizations in the twelve months of the year was evaluated. Moreover, blood chemistry assay and, for some patients, enzyme-linked immunosorbent assay were executed to evaluate antibodies. Regarding the severity of the disease, the bullous pemphigoid area index and the pemphigus disease area index score systems were used. Results showed a complex interplay between environmental factors such as seasons and autoimmune conditions.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9641"},"PeriodicalIF":1.1,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/e5/dr-15-3-9641.PMC10518530.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41118298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutaneous squamous cell carcinoma of the lip successfully treated with rhenium-188 brachytherapy. 铼-188近距离放疗成功治疗唇部皮肤鳞状细胞癌。
IF 1.1
Dermatology Reports Pub Date : 2023-06-14 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9560
Chiara Sabbadini, Federico Patta, Leda Lorenzon, Mohsen Farsad, Carla Nobile
{"title":"Cutaneous squamous cell carcinoma of the lip successfully treated with rhenium-188 brachytherapy.","authors":"Chiara Sabbadini,&nbsp;Federico Patta,&nbsp;Leda Lorenzon,&nbsp;Mohsen Farsad,&nbsp;Carla Nobile","doi":"10.4081/dr.2023.9560","DOIUrl":"https://doi.org/10.4081/dr.2023.9560","url":null,"abstract":"<p><p>Cutaneous squamous cell carcinoma (SCC) is the second most common form of skin cancer. In most cases, non-invasive SCC has a good prognosis and is curable by surgical resection. Nevertheless, a small percentage of patients pose specific management problems due to the technical difficulty of maintaining function and aesthetics because of the size or location of the tumor. An emerging therapeutic approach with high-dose brachytherapy using a nonsealed rhenium-188 resin, commercially known as Rhenium-Skin Cancer Therapy<sup>®</sup>, has been shown to be highly effective in non-invasive carcinoma, up to a thickness of 2-3 mm.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9560"},"PeriodicalIF":1.1,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/d5/dr-15-3-9560.PMC10543199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41103662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cicatricial alopecia associated with pemphigus. 伴天疱疮的瘢痕性脱发。
IF 1.1
Dermatology Reports Pub Date : 2023-06-14 eCollection Date: 2023-09-12 DOI: 10.4081/dr.2023.9653
Roberto D'Astolto, Chiara Zangrando, Claudio Feliciani
{"title":"Cicatricial alopecia associated with pemphigus.","authors":"Roberto D'Astolto,&nbsp;Chiara Zangrando,&nbsp;Claudio Feliciani","doi":"10.4081/dr.2023.9653","DOIUrl":"https://doi.org/10.4081/dr.2023.9653","url":null,"abstract":"<p><p>Pemphigus is a chronic autoimmune bullous disease associated with the production of autoantibodies directed against desmosomal proteins, such as desmogleins 1 and 3. Here, we present the case of an 83-year-old woman who was referred to us with suspicious cicatricial alopecia of the scalp and a small, eroded lesion on the forehead, previously labeled as atrophic actinic keratosis after a skin biopsy. In our clinic, after a careful examination of the case, we decided to perform two new skin biopsies of the scalp on suspicion of an inflammatory disease.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 3","pages":"9653"},"PeriodicalIF":1.1,"publicationDate":"2023-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/d8/dr-15-3-9653.PMC10543192.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41113290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus. 富马酸二甲酯在斑块型银屑病患者中的实际应用:基于德尔菲的专家共识。
IF 1.1
Dermatology Reports Pub Date : 2023-06-07 DOI: 10.4081/dr.2023.9613
Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi
{"title":"Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus.","authors":"Martina Burlando,&nbsp;Elena Campione,&nbsp;Aldo Cuccia,&nbsp;Giovanna Malara,&nbsp;Luigi Naldi,&nbsp;Francesca Prignano,&nbsp;Leonardo Zichichi","doi":"10.4081/dr.2023.9613","DOIUrl":"https://doi.org/10.4081/dr.2023.9613","url":null,"abstract":"<p><p>Dimethyl fumarate (DMF) was recently approved by the European Medicines Agency for systemic treatment of moderateto- severe chronic plaque psoriasis. Appropriate management of DMF treatment is required to achieve optimal clinical benefits. 7 dermatology experts gathered online for 3 meetings to identify consensus on the use of DMF in patient selection, drug dosage/titration, side effects management, and follow-up, with the aim to provide guidance on the use of DMF for psoriasis in clinical dermatological practice based on literature data and expert opinion. 20 statements were discussed and voted on using a facilitator- mediated modified Delphi methodology. Strong consensus was reached for all statements (agreement level of 100%). DMF treatment is characterized by dosage flexibility, sustained efficacy, high rates of drug survival, and low potential for drug-drug interactions. It can be used in a broad range of patients, including the elderly or those with comorbidities. Side effects (mainly gastrointestinal disorders, flushing, and lymphopenia) are frequently reported but are generally mild and transient and can be minimized by dosage adjustments and a slow titration schedule. Hematologic monitoring throughout the treatment course is required to reduce the risk of lymphopenia. This consensus document provides clinical dermatologists with answers on the optimal use of DMF to treat psoriasis.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9613"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/1c/dr-15-2-9613.PMC10327668.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The first reported case of erythrodermic sarcoidosis with systemic involvement during COVID-19 vaccination. 首例在COVID-19疫苗接种期间全身性感染的红皮病结节病报告病例。
IF 1.1
Dermatology Reports Pub Date : 2023-06-07 DOI: 10.4081/dr.2023.9636
Georgi Tchernev, Simona Kordeva, Heily Kirilova, Valentina Broshtilova
{"title":"The first reported case of erythrodermic sarcoidosis with systemic involvement during COVID-19 vaccination.","authors":"Georgi Tchernev,&nbsp;Simona Kordeva,&nbsp;Heily Kirilova,&nbsp;Valentina Broshtilova","doi":"10.4081/dr.2023.9636","DOIUrl":"https://doi.org/10.4081/dr.2023.9636","url":null,"abstract":"<p><p>Post-vaccinal and parainfectious activation of the immunity with subsequent development of a certain immunological/skinimmunological disease is not rare in clinical practice. This concept is mentioned in relation to molecular/antigenic mimicry. To this day, the pathogenesis of sarcoidosis and sarcoid-type reactions remains a mystery. Moreover, they can be a warning sign of changes in tissue homeostasis, whether they are infectious, noninfectious- immunological, tumor-related, <i>etc</i>. We present a rare form of erythrodermic sarcoidosis with massive systemic involvement (pericarditis, supraventricular tachycardia, hepatitis, iritis/iridocyclitis, pulmonary fibrosis/bihilar lymphadenopathy, and arthritis) developed after receiving the ChadOx1-S vaccine for COVID- 19. Systemic immunosuppressive therapy with Methylprednisolone was introduced according to a scheme (in a reduction mode with an initial dose of 40 mg/day intravenously) in combination with topical Pimecrolimus 1% cream twice a day. Rapid improvement of the symptoms was observed within the first two days of treatment. According to the scientific literature, the presented patient turns out to be the first case of erythrodermic sarcoidosis (with systemic involvement), described as a side effect after vaccination and/or administration of a certain medicinal form.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 2","pages":"9636"},"PeriodicalIF":1.1,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/8b/dr-15-2-9636.PMC10327692.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信